-
Birinapant
- names:
Birinapant
- CAS号:
1260251-31-7
MDL Number: - MF(分子式): C42H56F2N8O6 MW(分子量): 806.94
- EINECS: Reaxys Number:
- Pubchem ID: Brand:BIOFOUNT
| 货品编码 | 规格 | 纯度 | 价格 (¥) | 现价(¥) | 特价(¥) | 库存描述 | 数量 | 总计 (¥) |
|---|---|---|---|---|---|---|---|---|
| YZM000610-5mg | 5mg | 99.36% | ¥ 1890.00 | ¥ 1890.00 | 2-3天 | ¥ 0.00 | ||
| YZM000610-2mg | 2mg | 99.36% | ¥ 1105.00 | ¥ 1105.00 | 2-3天 | ¥ 0.00 |
| 中文别名 | |
| 英文别名 | |
| CAS号 | 1260251-31-7 |
| Inchi | |
| InchiKey | |
| 分子式 Formula | C42H56F2N8O6 |
| 分子量 Molecular Weight | 806.94 |
| 溶解度Solubility | 生物体外In Vitro:DMSO溶解度≥ 40 mg/mL(49.57 mM)H2O< 0.1 mg/mL(insoluble)*"≥" means soluble可溶, but saturation unknown溶解度未知. |
| 性状 | |
| 储藏条件 Storage conditions | 粉末Powder: -20°C 3 years年 4°C 2 years年 / In solvent溶液中:-80°C 6 months月 -20°C 1 month月 |
Birinapant(CAS:1260251-31-7)实验注意事项:
1.实验前需戴好防护眼镜,穿戴防护服和口罩,佩戴手套,避免与皮肤接触。
2.实验过程中如遇到有毒或者刺激性物质及有害物质产生,必要时实验操作需要手套箱内完成以免对实验人员造成伤害
3.实验后产生的废弃物需分类存储,并交于专业生物废气物处理公司处理,以免造成环境污染Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.
1.实验前需戴好防护眼镜,穿戴防护服和口罩,佩戴手套,避免与皮肤接触。
2.实验过程中如遇到有毒或者刺激性物质及有害物质产生,必要时实验操作需要手套箱内完成以免对实验人员造成伤害
3.实验后产生的废弃物需分类存储,并交于专业生物废气物处理公司处理,以免造成环境污染Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.
| 产品说明 | Birinapant (TL32711) 是一种有效的二价 Smac 模拟物,为XIAP和cIAP1的强效拮抗剂,Kd值分别为 45 nM 和小于 1 nM |
| Introduction | Birinapant (TL32711), a bivalent Smac mimetic, is a potent antagonist forXIAPandcIAP1withKds of 45 nM and less than 1 nM, respectively. Birinapant (TL32711) induces the autoubiquitylation and proteasomal degradation of cIAP1 and cIAP2 in intact cells, which results in formation of a RIPK1: caspase complex, caspase activation, and induction of tumor cell death. Birinapant (TL32711) targets TRAF2ssociated cIAPs and abrogates TNFnduced NFB activation. |
| Application1 | |
| Application2 | |
| Application3 |
Birinapant (TL32711) 是一种有效的二价 Smac 模拟物,为XIAP和cIAP1的强效拮抗剂,Kd值分别为 45 nM 和小于 1 nM。Birinapant (TL32711) 诱导完整细胞中 cIAP1 和 cIAP2 的自身泛素化和蛋白酶体降解,从而形成 RIPK1: caspase-8 复合物,caspase-8 活化和诱导肿瘤细胞死亡。Birinapant (TL32711) 靶向与 TRAF2 相关的 cIAP,并消除 TNF 诱导的 NF-κB 活化。Birinapant (TL32711), a bivalent Smac mimetic, is a potent antagonist forXIAPandcIAP1withKds of 45 nM and less than 1 nM, respectively. Birinapant (TL32711) induces the autoubiquitylation and proteasomal degradation of cIAP1 and cIAP2 in intact cells, which results in formation of a RIPK1: caspase-8 complex, caspase-8 activation, and induction of tumor cell death. Birinapant (TL32711) targets TRAF2-associated cIAPs and abrogates TNF-induced NF-κB activation.
【1】.Allensworth JL, et al. Smac mimetic Birinapant induces apoptosis and enhances TRAIL potency in inflammatory breast cancer cells in an IAP-dependent and TNF-α-independent mechanism. Breast Cancer Res Treat. 2013 Jan;137(2):359-71.
【2】.Krepler C, et al. The novel SMAC mimetic birinapant exhibits potent activity against human melanoma cells. Clin Cancer Res. 2013 Apr 1;19(7):1784-94.
【3】.Nguyen QD, et al. Temporal and spatial evolution of therapy-induced tumor apoptosis detected by caspase-3-selective molecular imaging. Clin Cancer Res. 2013 Jul 15;19(14):3914-24.
【4】.Benetatos CA, et al. Birinapant (TL32711), a bivalent SMAC mimetic, targets TRAF2-associated cIAPs, abrogates TNF-induced NF-κB activation, and is active in patient-derived xenograft models. Mol Cancer Ther. 2014 Apr;13(4):867-79.
【2】.Krepler C, et al. The novel SMAC mimetic birinapant exhibits potent activity against human melanoma cells. Clin Cancer Res. 2013 Apr 1;19(7):1784-94.
【3】.Nguyen QD, et al. Temporal and spatial evolution of therapy-induced tumor apoptosis detected by caspase-3-selective molecular imaging. Clin Cancer Res. 2013 Jul 15;19(14):3914-24.
【4】.Benetatos CA, et al. Birinapant (TL32711), a bivalent SMAC mimetic, targets TRAF2-associated cIAPs, abrogates TNF-induced NF-κB activation, and is active in patient-derived xenograft models. Mol Cancer Ther. 2014 Apr;13(4):867-79.
对不起,暂无产品评价!
MSDS
SDS 1.0 中文
展开
SDS 1.0 英文
展开
- 相关产品
-
< >
- 推荐产品
-
< >
- 最新产品
-
< >
新闻
抱歉,暂无数据!


购物车 


